Loading...
MIT Sloan Health Systems Initiative (HSI) Lunch Seminar Series with Delfi Krishna
Registration
Registration is now closed (this event already took place).
Details
Thursday, April 13, 2023
E62-450
11:45am - 1pm 
Join Zoom Meeting
https://tinyurl.com/588skc8x
Password: 100
One tap mobile
+16465588656,,93963234492
Meeting ID: 939 6323 4492
Lunch will be provided
Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications, in some cases offering the possibility of a disease cure with a single treatment. This presentation will discuss the multi-disciplinary business environment required to bring these cutting-edge medicines to patients.
 
Delfi Krishna is currently the Vice President of Cell Therapy Portfolio Development at Immatics – a German biotech company with the mission to bring the power of T-cells to cancer patients. She has a Ph.D in Chemical and Biomolecular Engineering from Georgia Tech and is currently an Executive MBA student at MIT Sloan.
Speakers
Delfi Krishna
Vice President of Cell Therapy Portfolio Development
Immatics
She is currently the Vice President of Cell Therapy Portfolio Development at Immatics – a German biotech company with the mission to bring the power of T-cells to cancer patients. She is accountable to c-suite for delivery of a cell therapy portfolio strategy that enables continuous financing in capital markets and positions Immatics in the top league of biotechs.
She has a Ph.D in Chemical and Biomolecular Engineering from Georgia Tech and is currently an Executive MBA student at MIT Sloan.